BioSpace News Archive

Amneal Pharmaceuticals, Inc. announced the release of its third annual Environmental, Social and Governance Report.

bioAffinity Technologies, Inc., a biotechnology company addressing the need for early-stage cancer detection and broad-spectrum cancer therapeutics, will present the poster “Vitamin B12 deprivation does not phenocopy selective cytotoxicity of CD320 and LRP2 silencing” at the University of Massachusetts T.H. Chan Medical School’s fifth annual RNA Therapeutics Symposium June 21-23, 2023, in Worcester, MA.

GlycoMimetics, Inc. a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, announced the U.S. Food and Drug Administration cleared the addition of a protocol amendment to the company’s pivotal Phase 3 study of uproleselan for relapsed/refractory Acute Myeloid Leukemia.

Endologix LLC, a privately held, global medical device company, dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced the 24-month results of the DETOUR2 Study.

Hepion Pharmaceuticals, Inc. announced that the Data and Safety Monitoring Board has met to review the current data for the ASCEND-NASH Phase 2b trial and has issued a “study may proceed without modification” clearance.

Polydex Pharmaceuticals Limited reports financial results for the first quarter of fiscal 2024, the period ended April 30, 2023.

CorMedix Inc. announced its first-of-kind strategic initiative with Boston Medical Center to enhance patient safety and reduce health disparities in structurally marginalized populations at risk for bloodstream infections while undergoing dialysis.

Diurnal Ltd., a Neurocrine Biosciences company, announced that it will present new post hoc analyses of Phase 3 extension study data for modified-release hydrocortisone, which is being investigated as a treatment for adults with congenital adrenal hyperplasia, at ENDO 2023 June 15–18 in Chicago.

Mallinckrodt plc announced that two scientific posters detailing Mallinckrodt’s latest research findings on the clinical outcomes of treatment with TERLIVAZ® for injection and clinical management criteria for adult patients with hepatorenal syndrome will be presented at the European Association for the Study of the Liver Congress 2023 in Vienna, Austria, taking place June 21-24, 2023.

IDEXX Laboratories, Inc., a global leader in pet healthcare innovation, announced the launch of the first veterinary diagnostic test for detecting kidney injury in cats and dogs.